Becton, Dickinson and Company (NYSE:BDX) Given Average Rating of “Buy” by Brokerages

Becton, Dickinson and Company (NYSE:BDX) has earned an average rating of “Buy” from the fifteen analysts that are covering the stock, MarketBeat reports. Seven analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $281.36.

A number of analysts have recently weighed in on the stock. Raymond James boosted their price objective on shares of Becton, Dickinson and from $270.00 to $282.00 and gave the stock an “outperform” rating in a research note on Friday, January 29th. TheStreet upgraded shares of Becton, Dickinson and from a “c+” rating to an “a-” rating in a research note on Thursday, February 4th. Piper Sandler upped their target price on shares of Becton, Dickinson and from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, February 4th. Citigroup upped their target price on shares of Becton, Dickinson and from $273.00 to $280.00 and gave the company a “neutral” rating in a research note on Friday, February 5th. Finally, Zacks Investment Research lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating and set a $276.00 price target on the stock. in a report on Wednesday, January 13th.

NYSE BDX traded down $2.53 during trading on Thursday, reaching $250.59. The company’s stock had a trading volume of 18,994 shares, compared to its average volume of 1,312,288. The company has a current ratio of 1.54, a quick ratio of 1.07 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $72.81 billion, a PE ratio of 92.72, a PEG ratio of 2.34 and a beta of 0.79. The business has a 50-day moving average price of $247.90 and a 200-day moving average price of $246.48. Becton, Dickinson and has a 1-year low of $219.50 and a 1-year high of $284.97.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.14 by $1.41. Becton, Dickinson and had a net margin of 5.11% and a return on equity of 13.30%. The firm had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $4.87 billion. During the same period in the previous year, the company earned $2.65 earnings per share. The company’s revenue was up 25.8% compared to the same quarter last year. As a group, analysts expect that Becton, Dickinson and will post 12.5 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 30th. Shareholders of record on Wednesday, June 9th will be issued a dividend of $0.83 per share. This represents a $3.32 dividend on an annualized basis and a yield of 1.32%. The ex-dividend date is Tuesday, June 8th. Becton, Dickinson and’s dividend payout ratio is currently 32.55%.

A number of large investors have recently modified their holdings of the business. Grant Street Asset Management Inc. grew its holdings in Becton, Dickinson and by 8.0% during the 1st quarter. Grant Street Asset Management Inc. now owns 1,081 shares of the medical instruments supplier’s stock worth $263,000 after acquiring an additional 80 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in Becton, Dickinson and by 2.1% during the 1st quarter. Commonwealth Equity Services LLC now owns 80,094 shares of the medical instruments supplier’s stock valued at $19,474,000 after purchasing an additional 1,661 shares during the period. Sterling Investment Advisors Ltd. lifted its position in Becton, Dickinson and by 15.7% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 4,645 shares of the medical instruments supplier’s stock valued at $1,129,000 after purchasing an additional 630 shares during the period. Vicus Capital raised its position in shares of Becton, Dickinson and by 4.8% in the 1st quarter. Vicus Capital now owns 1,462 shares of the medical instruments supplier’s stock valued at $355,000 after acquiring an additional 67 shares during the period. Finally, Victory Capital Management Inc. raised its position in shares of Becton, Dickinson and by 1.1% in the 1st quarter. Victory Capital Management Inc. now owns 100,375 shares of the medical instruments supplier’s stock valued at $24,406,000 after acquiring an additional 1,084 shares during the period. 83.22% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: Market Perform

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.